MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Supernus Pharmaceuticals Company Profile (NASDAQ:SUPN)

Consensus Ratings for Supernus Pharmaceuticals (NASDAQ:SUPN) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.00 (24.73% upside)

Analysts' Ratings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Show:
DateFirmActionRatingPrice TargetActions
5/12/2016Jefferies GroupReiterated RatingBuy$19.00 -> $23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2016Piper JaffrayReiterated RatingOverweight$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016Northland SecuritiesReiterated RatingOutperform$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/18/2015Stifel NicolausBoost Price TargetBuy$15.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/12/2015SunTrustInitiated CoverageBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015GuggenheimInitiated CoverageBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/3/2016Q1$0.09$0.08$45.33 million$43.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2016Q4$0.06$0.14$42.93 million$42.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315$0.02$0.08$37.93 million$38.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215$0.02$0.03$34.07 million$35.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015$0.02$0.02$29.16 million$28.13 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014Q314$0.36$0.39$43.10 million$52.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.16)$0.08$19.85 million$29.67 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.41)($0.38)$9.94 million$9.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2014Q413($0.55)($0.65)$7.78 million$10.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q313($0.67)($0.78)$2.54 million$1.26 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2013Q2 2013($0.65)($0.89)$0.91 million$0.28 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.62)($0.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.06$0.10$0.08
Q2 20162$0.13$0.13$0.13
Q3 20162$0.19$0.23$0.21
Q4 20162$0.22$0.27$0.25
(Data provided by Zacks Investment Research)
Dividend History for Supernus Pharmaceuticals (NASDAQ:SUPN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/11/2016Padmanabh P BhattVPSell30,762$16.49$507,265.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Padmanabh P. BhattVPSell14,238$14.90$212,146.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2015M James BarrettDirectorSell212,970$14.56$3,100,843.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2015M James BarrettDirectorSell16,179$16.35$264,526.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2015M James BarrettDirectorSell93,000$16.61$1,544,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015M James BarrettDirectorSell119,650$16.24$1,943,116.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2015Padmanabh P BhattVPSell5,000$19.90$99,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2015Gregory S PatrickCFOSell6,217$20.00$124,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Stefan K.F. SchwabeEVPSell1,950$19.23$37,498.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2015M James BarrettDirectorSell111,881$16.39$1,833,729.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2015Scott D SandellMajor ShareholderSell136,597$16.50$2,253,850.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015M James BarrettDirectorSell55,105$16.85$928,519.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015Scott D SandellMajor ShareholderSell95,437$16.92$1,614,794.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015Stefan K.F. SchwabeEVPSell2,051$18.27$37,471.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2015Stefan K.F. SchwabeEVPSell3,631$16.39$59,512.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2015Jones W BryanVPSell1,900$12.00$22,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2013Padmanabh BhattVPSell2,285$8.21$18,759.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2013Michael BighamDirectorBuy35,000$5.41$189,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2013John M SiebertDirectorBuy3,000$5.50$16,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2013Jack A KhattarCEOBuy10,000$6.15$61,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2013Gregory S PatrickCFOBuy5,000$6.95$34,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2012John M SiebertDirectorBuy7,000$8.14$56,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Supernus Pharmaceuticals (NASDAQ:SUPN)
DateHeadline
06/24/16 09:11 AMRecently Issued Stock Ratings For Supernus Pharmaceuticals, Inc. (SUPN) - Fiscal Standard
06/22/16 06:34 PMSupernus Pharmaceuticals, Inc. (NasdaqGM:SUPN) Stock Momentum Hits Strength - CML News
06/22/16 06:34 PMSupernus Pharmaceuticals Inc. (SUPN) is Trading Higher on Unusual Volume for June 20 - Equities.com
06/22/16 06:34 PMSupernus Pharma (SUPN) Issued Seventh U.S. Patent Related to Oxtellar XR - StreetInsider.com
06/22/16 03:30 PM4:30 pm Supernus Pharma announces the issuance of a seventh patent covering Oxtellar XR -
06/22/16 03:30 PMSupernus Announces Issuance of Seventh U.S. Patent Protecting Oxtellar XR® - [GlobeNewswire] - ROCKVILLE, Md., June 22, 2016-- Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, ...
06/20/16 08:07 AMSupernus Pharmaceuticals, Inc. (SUPN) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 06:20 PMCAPR Vaults On Study, CRBP Awaits Data In Q4, OASIS A Shot In The Arm For PRTK
06/17/16 06:20 PMSupernus Pharmaceuticals : Pharma (SUPN) Still in Talks with FDA Over Trokendi XR sNDA; Reaffirms Outlook
06/17/16 09:18 AMSupernus Pharma (SUPN) Still in Talks with FDA Over Trokendi XR sNDA; Reaffirms Outlook
06/16/16 06:50 PMSupernus Pharma (SUPN) Still in Talks with FDA Over Trokendi XR sNDA; Reaffirms Outlook - StreetInsider.com
06/16/16 03:49 PMSupernus Provides Update on Trokendi XR® Migraine sNDA and Reiterates Guidance - [at noodls] - June 16, 2016 ROCKVILLE, Md., June 16, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the ...
06/09/16 12:30 PMETF’s with exposure to Supernus Pharmaceuticals, Inc. : June 9, 2016 -
06/08/16 08:36 AMSupernus Pharmaceuticals, Inc. :SUPN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
06/05/16 09:22 AMOpaleye Management INC Decreased Stake in Supernus Pharmaceuticals INC (NASDAQ:SUPN) by $4.43 Million as ... - CCH Daily News
06/04/16 09:39 AMTrader's Healthcare Focused Stocks: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) , Charles River Laboratories ... - Is stories
06/02/16 09:50 AMSupernus Pharma (SUPN) Receives Sixth U.S. Patent Related to Oxtellar XR - StreetInsider.com - Supernus Pharma (SUPN) Receives Sixth U.S. Patent Related to Oxtellar XRStreetInsider.comSupernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced the issuance on May 31, 2016 of a sixth patent (number 9,351,975) by the United States Patent and Trademark Office (USPTO) covering Oxtellar XR, its novel once-daily extended-release ...and more »
06/02/16 07:15 AMSupernus Announces Issuance of Sixth U.S. Patent Protecting Oxtellar XR® - [at noodls] - June 2, 2016 ROCKVILLE, Md., June 02, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the ...
06/01/16 09:39 AMStock Review and Earnings Check on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - HNN - Stock Review and Earnings Check on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Supernus Pharmaceuticals, Inc.and more »
05/30/16 10:21 PMNext Weeks Broker Price Targets For Supernus Pharmaceuticals, Inc. (SUPN) - Share Trading News - Next Weeks Broker Price Targets For Supernus Pharmaceuticals, Inc. (SUPN)Share Trading News06/18/2015 – Supernus Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 22 price target on the stock. 06/12/2015 – SunTrust began new coverage on Supernus Pharmaceuticals, Inc. giving the company ...Bruce Lowers stake in Supernus Pharmaceuticals Inc (SUPN)Market DigestSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) One-Year Price Target At $27.29Stocks DailyMurphy Michael R Decreased Stake in Supernus Pharmaceuticals INC (NASDAQ:SUPN) by $5.68 Million as Shares ...CCH Daily NewsThe Post -Investor Newswire -Franklin Independentall 7 news articles »
05/28/16 07:03 PMMurphy Michael R Decreased Stake in Supernus Pharmaceuticals INC (NASDAQ:SUPN) by $5.68 Million as Shares ... - CCH Daily News - Murphy Michael R Decreased Stake in Supernus Pharmaceuticals INC (NASDAQ:SUPN) by $5.68 Million as Shares ...CCH Daily NewsMurphy Michael R decreased its stake in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 41.17% based on its latest 2016Q1 regulatory filing with the SEC. Murphy Michael R sold 378,989 shares as the company's stock rose 16.06% with the market.Bruce Lowers stake in Supernus Pharmaceuticals Inc (SUPN)Market DigestSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) EPS Estimate At $0.18Investor NewswireIs it Time to Cash in Profits on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Franklin Independentall 4 news articles »
05/26/16 06:53 AMEarnings Review and Stock Rundown for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Wall Street Hints and News - Earnings Review and Stock Rundown for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Supernus Pharmaceuticals, Inc.and more »
05/26/16 06:53 AMSupernus Pharmaceuticals, Inc. (SUPN) Updated Price Targets - FTSE News - Supernus Pharmaceuticals, Inc. (SUPN) Updated Price TargetsFTSE News06/18/2015 – Supernus Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 22 price target on the stock. 06/12/2015 – SunTrust began new coverage on Supernus Pharmaceuticals, Inc. giving the company ...Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Costs Of Goods Sold Stands At $8.423 MillionsStocks DailyRecently Changed Price Targets On Supernus Pharmaceuticals, Inc. (SUPN)Risers & Fallersall 3 news articles »
05/24/16 04:36 PMSupernus to Present at June Jefferies Healthcare Conference - [at noodls] - May 24, 2016 ROCKVILLE, Md., May 24, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the ...
05/24/16 12:20 AM4 Stocks To Watch: NTRA, OLED, SLCA, SUPN - It has 4.76 days to cover. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has done very well in the last 3-4 months after the big reversal day in February, going from under 10 to nearly 18 1/2, but the 18 1/2 level broke down, which means Monday’s high was ...
05/23/16 07:07 PMStock Rating Review for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Wall Street Hints and News - Stock Rating Review for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1 on shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research.and more »
05/23/16 07:07 PMSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Impact Score At 0 - RealistInvestor.com - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Impact Score At 0RealistInvestor.comAlpha One explored various online articles released on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), and it set a daily sentiment score of 0.343 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring ...and more »
05/22/16 11:51 AMSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) One-Year Price Target Estimate At $27.29 - Investor Newswire - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) One-Year Price Target Estimate At $27.29Investor NewswireThe 52-week price target of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is set at $27.29 after First Call completed its market based survey. It has estimated EPS of $0.17 for approaching quarter and $0.63 for ongoing year. The EPS estimate for next ...and more »
05/21/16 06:38 PMJefferies Maintains Supernus Pharmaceuticals Inc to Buy with Price Target $23.00 - Trade Calls - Jefferies Maintains Supernus Pharmaceuticals Inc to Buy with Price Target $23.00Trade CallsBrokerage firm Jefferies Maintains its rating on Supernus Pharmaceuticals Inc(NASDAQ:SUPN). In a research note issued to the investors, the brokerage major Raises the price-target to $23.00 per share. The shares have been rated Buy. The rating by ...Supernus Pharmaceuticals Incorporated (NASDAQ:SUPN) Shorted Shares Decreased By 5.84%Franklin Independentall 3 news articles »
05/21/16 12:13 AMRevenue Update on Supernus Pharmaceuticals Inc(NASDAQ:SUPN) - Trade Calls - Revenue Update on Supernus Pharmaceuticals Inc(NASDAQ:SUPN)Trade CallsSupernus Pharmaceuticals Inc(NASDAQ:SUPN) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 3, 2016. Company reported revenue of $43.08M. Analysts estimated a revenue of $45.33M.
05/20/16 07:05 PMSupernus Pharmaceuticals, Inc. (SUPN) Updated Broker Price Targets - Share Trading News - Supernus Pharmaceuticals, Inc. (SUPN) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Supernus Pharmaceuticals, Inc. (SUPN). The latest reports which are currently in issue on Friday 20th of May state 0 analysts have a rating of “strong buy”, 0 analysts ...Upgrades And Downgrades For Supernus Pharmaceuticals, Inc. (SUPN)Risers & Fallersall 6 news articles »
05/19/16 07:08 PMTrading updates about two Stocks: Sanofi (NYSE:SNY) , Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Street Updates - Trading updates about two Stocks: Sanofi (NYSE:SNY) , Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Street UpdatesOn 5/18/2016, shares of Sanofi (NYSE:SNY) fell -0.05% in trading session and finally closed at $39.44. The company most recent volume stood at 1.46 million shares as compared to its average volume of 2.05 million shares. Over the one year trading ...and more »
05/19/16 03:36 PMSUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/18/16 07:08 PMShare Recap and Earnings Focus on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Wall Street Hints and News - Share Recap and Earnings Focus on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Wall Street Hints and NewsPresently, covering analysts are anticipating Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to report quarterly EPS of $0.13. The company's next earnings report is expected to be released on or around 2016-08-02 for the period ending on 2016-06-30.and more »
05/18/16 11:33 AMSupernus Pharmaceuticals Inc. (SUPN) is Trading Higher on Unusual Volume for May 16 - Equities.com - Supernus Pharmaceuticals Inc. (SUPN) is Trading Higher on Unusual Volume for May 16Equities.comSupernus Pharmaceuticals Inc. (SUPN) experienced unusually high volume on May. 16, as the stock gained 2.26% to a closing price of $17.67. The stock saw 889,749 shares trade hands over the course of the day on 6,856 trades. Given that the stock's ...
05/17/16 11:31 AMSupernus Pharmaceuticals, Inc. (SUPN) Broker Price Targets For The Coming Week - Share Trading News - Supernus Pharmaceuticals, Inc. (SUPN) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Supernus Pharmaceuticals, Inc. (SUPN). The latest reports which are currently in issue on Tuesday 17th of May state 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
05/16/16 06:50 PMConsensus Rating Review for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Wall Street Hints and News - Consensus Rating Review for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1 on shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, ...and more »
05/16/16 12:33 PMBulls to Watch: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM ... - KC Register - Bulls to Watch: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM ...KC RegisterSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) announced that, pursuant to a confidential partial settlement agreement, it has dismissed two patent infringement actions pending in the U.S. District Court for the District of New Jersey against Actavis Inc ...and more »
05/16/16 12:32 PMAlpha One Assigns Impact Score Of 0 To Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - RealistInvestor.com - Alpha One Assigns Impact Score Of 0 To Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)RealistInvestor.comAlpha One analyzed the various web articles published on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), and thereafter it gave company a daily sentiment score of 0.447. The entity designs algorithm based assessment to known stock sentiment on stock ...and more »
05/16/16 12:32 PMStocks Earnings Analysis Report: Supernus Pharmaceuticals Inc (NASDAQ:SUPN) - News Oracle - News OracleStocks Earnings Analysis Report: Supernus Pharmaceuticals Inc (NASDAQ:SUPN)News OracleLast Trade: The Company rose 6.21% and finished at $17.28. The daily volume was measured at 1.03 million shares. The 52-week high of the share price is $23.30 and the 52-week low is $9.51. The company has a market cap of $907.01 million. The stock ...
05/14/16 12:48 AMWhy Supernus Pharmaceuticals Inc (NASDAQ:SUPN) is an Excellent Choice? - Street Report - Why Supernus Pharmaceuticals Inc (NASDAQ:SUPN) is an Excellent Choice?Street Report[EDGAR] Supernus Pharmaceuticals Inc (NASDAQ:SUPN)(TREND ANALYSIS) the Company issued a press release announcing a partial settlement with Actavis of ongoing patent litigation. A copy of this press release is furnished as Exhibit 99.1 hereto and ...and more »
05/10/16 07:50 PMPerformance Recap and Target Perspective on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - B.O.D.Y Confidential - Performance Recap and Target Perspective on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)B.O.D.Y ConfidentialIn the latest trading session, shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) moved +5.29%. In order to gain some further insight on stock performance, we can take a look at the stock price relative to some moving averages. After a recent check ...and more »
05/10/16 07:50 PMSupernus Pharma (SUPN) Enters Partial Settlement Over Oxtellar XR Patent Actions - StreetInsider.com - Supernus Pharma (SUPN) Enters Partial Settlement Over Oxtellar XR Patent ActionsStreetInsider.comSupernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced that, pursuant to a confidential partial settlement agreement, it has dismissed two patent infringement actions pending in the U.S. District Court for the District of New Jersey against Actavis ...and more »
05/10/16 03:23 PMSUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
05/10/16 05:06 AMSUPERNUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report -
05/09/16 07:18 PMCheck on Analyst Ratings Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - B.O.D.Y Confidential - Check on Analyst Ratings Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)B.O.D.Y ConfidentialCovering Wall Street analysts have an average rating of 1 on shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating falls on a 1 to 5 ...and more »
05/09/16 07:18 PMAnalysis EPS Report overview: Supernus Pharmaceuticals Inc (SUPN) - News Oracle - NewsWay 21Analysis EPS Report overview: Supernus Pharmaceuticals Inc (SUPN)News OracleLast Trade: The Company fell -3.26% and finished at $15.12. The daily volume was measured at 1.22 million shares. The 52-week high of the share price is $23.30 and the 52-week low is $9.51. The company has a market cap of $722.66 million. Its latest ...After Last Week What Do Analysts Think Of Supernus Pharmaceuticals, Inc. (SUPN)Share Trading NewsSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Yearly EPS Target At $0.63Investor NewswireSupernus Pharmaceuticals Incorporated (NASDAQ:SUPN) Short Interest Increased By 2.33%The Postall 12 news articles »
05/09/16 07:18 PMSupernus Pharmaceuticals Inc. (SUPN) Jumps 5.29% on May 09 - Equities.com - Supernus Pharmaceuticals Inc. (SUPN) Jumps 5.29% on May 09Equities.comSupernus Pharmaceuticals Inc. (SUPN) was among the biggest gainers on the Russell 2000 for Monday May 09 as the stock popped 5.29% to $15.92, representing a gain of $0.8 per share. Some 475,135 shares traded hands on 4,018 trades, compared with ...
05/04/16 08:00 AMSupernus Pharmaceuticals Inc Earnings Call scheduled for 9:00 am ET today -
05/04/16 05:03 AMSUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -
About Supernus Pharmaceuticals

Supernus Pharmaceuticals logoSupernus Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder), and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR, Trokendi XR, SPN-810, SPN-812 and SPN-809.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: SUPN
  • CUSIP: 86845910
Key Metrics:
  • Previous Close: $18.44
  • 50 Day Moving Average: $18.32
  • 200 Day Moving Average: $15.14
  • P/E Ratio: 54.56
  • P/E Growth: 0.40
  • Market Cap: $911.32M
  • Current Quarter EPS Consensus Estimate: $0.62 EPS
Additional Links:
Supernus Pharmaceuticals (NASDAQ:SUPN) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha